NCT03687710Enrolling by invitation
The Comparative Effectiveness Dementia & Alzheimer's Registry
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
To evaluate the effectiveness of using clinical precision medicine to develop lifecourse interventions for Alzheimer's disease (AD) prevention and treatment. Anthropometrics, blood biomarkers (including genetics), and cognition will measured longitudinally to assess the comparative effectiveness of clinical care.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 452 (estimated)
- First submitted
- 6 Sept 2018
- Start date
- 16 Feb 2015
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- Weill Medical College of Cornell University
- Diseases
- Alzheimer disease
- NCT number
- NCT03687710
What you commit to
- Study type: Observational
- Planned participants: 452
- From 16 Feb 2015 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- none
Who the study is looking for
- 18 years of age or older
- family history of Alzheimer's disease and no cognitive complaints OR subjective cognitive decline OR preclinical AD OR mild cognitive impairment due to AD or other conditions
Age in the registry: 18 years to 99 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Weill Cornell Medicine Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.